KOD

Kodiak Sciences Inc.

Fundamental data last updated:September 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

 


Analyze KOD on TradingView

VALUATION

P/E

-9.69

Market Cap ($M USD)

$1.91B

Forward P/E

9.02

PEG

0.04

PRICE TO SALES

0.00

PRICE TO BOOK

19.93

EV / EBITDA

-8.78

5-Year Average P/E

Free Cash Flow Yield

-7.75%

DCF Value

$2.62

Graham Number

N/A

Price to FCF

-12.91

EV to FCF

-12.14

Earnings Yield

-10.32%

FCF Yield

-7.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.73

Next Year EPS Growth Estimate

$4.01

Next Year Revenue Growth Estimate

$870.81M

Return on Equity (ROE)

-253.85%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.38

Piotroski F-Score

1

Altman Z-Score

-3.48

Return on Invested Capital (ROIC)

-91.68%

Current Ratio

3.54

Quick Ratio

3.54

Net Debt to EBITDA

0.55

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-2.39

REVENUE PER SHARE

$0.00

Analyze KOD on TradingView

Gainseekers Quantitative Analysis

Summary

Kodiak Sciences Inc. presents a perplexing valuation conundrum. Despite a Forward P/E of 10.44 suggesting future profitability, the stock’s current price is dramatically misaligned with its DCF Value, indicating potential overvaluation. The negative Altman Z-score of -2.74 signals financial distress, while an earnings yield of -9.09% underscores its current unprofitability. The market appears to be pricing in a turnaround, but the financial health remains precarious, with a Price/Book ratio of 22.63 hinting at speculative optimism rather than intrinsic value.

AI Exposure / Tech Reliance

As a biotechnology firm, Kodiak Sciences is inherently positioned to leverage AI and tech advancements in drug discovery and development. The industry's rapid adoption of AI for personalized medicine and predictive analytics could enhance its R&D efficiency. However, the company's current financial metrics suggest it must first stabilize its core operations to fully capitalize on these technological shifts.

The Bull Case

For the bold investor, Kodiak Sciences offers a tantalizing speculative play. The Forward PEG ratio of 0.05 suggests significant growth potential relative to its price, a rare find in the biotech sector. Despite a dismal Piotroski F-Score of 1, the company's low debt/equity ratio of 0.38 provides a cushion for future investments. The current ratio of 3.54 indicates robust liquidity, suggesting that while the company struggles with profitability, it has the means to navigate short-term challenges.

The Bear Case

The bear case for Kodiak Sciences is stark. With a Price/Book ratio of 22.63 and a Price to FCF of -14.65, the stock is priced for perfection without delivering on fundamentals. The negative ROIC of -91.68% and a gross profit margin of zero highlight severe operational inefficiencies. Furthermore, trading near its 52-week high with a 16.65% distance, the stock appears technically overextended, leaving little room for error in execution.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$63.75

Institutional Ownership %

1-Year Beta

2.32

Insider Buying % (6 Mo)

Distance to 52-Week High

32.45%

Distance to 52-Week Low

90.97%

EARNINGS SURPRISE %

-1.08%

50-DAY SMA

$38.67

200-DAY SMA

$24.56

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.